List of Excipients in Branded Drug XENLETA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Meitheal Pharmaceuticals Inc	XENLETA	lefamulin acetate	71288-039	SODIUM CHLORIDE	2033-03-25
Meitheal Pharmaceuticals Inc	XENLETA	lefamulin acetate	71288-039	WATER	2033-03-25
Nabriva Therapeutics US Inc	XENLETA	lefamulin acetate	72000-120	SODIUM CHLORIDE	2033-03-25

XENLETA Excipient Strategy and Commercial Opportunities for Lefamulin

Last updated: September 14, 2026

XENLETA, the brand name for lefamulin, has a two-formulation commercial strategy: a 600 mg oral tablet and a 150 mg/15 mL intravenous formulation. The product is FDA-approved for adults with community-acquired bacterial pneumonia, or CABP. Its excipient opportunity is strongest in lifecycle management rather than direct substitution of the approved commercial formulations. Potential value areas include pediatric oral dosage forms, ready-to-use intravenous presentations, improved tablet tolerability, hospital-use packaging, and differentiated formulations for step-down therapy.

What formulations and excipients are used in XENLETA?

XENLETA is supplied as an oral film-coated tablet and as a single-dose intravenous solution. The oral and injectable products require different excipient strategies because the tablet must support high-dose delivery and oral tolerability, while the injection must maintain chemical stability, sterility, isotonicity, and infusion compatibility.

Product	Strength	Administration	Commercial role
XENLETA tablets	600 mg	Oral, every 12 hours	Outpatient and oral step-down treatment
XENLETA injection	150 mg/15 mL	Intravenous infusion over 60 minutes, every 12 hours	Hospital initiation and patients unable to take oral therapy

The FDA prescribing information identifies inactive ingredients in the tablet that include lactose monohydrate, crospovidone, magnesium stearate, povidone, sodium lauryl sulfate, colloidal silicon dioxide and film-coating components. The injectable formulation contains buffering and tonicity-adjusting components in water for injection, including citrate-based excipients and sodium chloride, according to the approved product information.[1]

What does the tablet excipient system do?

The 600 mg tablet presents a high drug-load challenge. The core excipients must provide adequate powder flow, tablet strength, disintegration and manufacturing consistency without creating an excessively large dosage form.

The principal functions are:

• Lactose monohydrate: diluent and tablet-mass builder.
• Crospovidone: disintegrant for rapid breakup after administration.
• Povidone: binder that supports granulation and tablet integrity.
• Magnesium stearate: lubricant for compression and ejection.
• Colloidal silicon dioxide: glidant that improves powder flow.
• Sodium lauryl sulfate: wetting agent that can support dissolution of a poorly water-soluble active pharmaceutical ingredient.
• Film-coating excipients: protection, identification, swallowability and surface handling.

Because lefamulin is a pleuromutilin antibiotic with limited aqueous solubility, wetting and dissolution control are important formulation functions. The tablet must also be used under food restrictions. The FDA label instructs patients to take oral XENLETA at least one hour before or two hours after food, which limits the commercial value of formulations that rely on food-mediated absorption.[1]

What excipient opportunities exist for XENLETA tablets?

The most practical opportunities are incremental. A replacement tablet must preserve the rapid-release profile, support a 600 mg dose and avoid further complicating food administration.

High-value tablet opportunities

Opportunity	Relevant excipient or technology	Commercial rationale
Smaller tablet	High-density filler, direct compression, granulation optimization	Improves swallowing and adherence
Lower gastrointestinal irritation	Alternative surfactant or lower sodium lauryl sulfate load	May improve tolerability
Lactose-free presentation	Microcrystalline cellulose, mannitol or other diluent	Expands use in patients avoiding lactose
Improved dissolution	Wetting agents, co-processing, amorphous or solid-dispersion approaches	Protects exposure and batch consistency
Pediatric taste masking	Polymer coating, ion-exchange resin, multiparticulate technology	Enables age-appropriate dosing
Low-moisture packaging	Desiccants and high-barrier blister systems	Protects tablet stability during distribution

A lactose-free tablet could address a narrow but commercially identifiable segment. The opportunity is more credible if the current tablet has meaningful lactose exposure or if hospital formularies seek simplified excipient profiles. The economic case would depend on whether a reformulated product receives separate regulatory protection or merely competes as a lower-cost alternative.

Reducing or replacing sodium lauryl sulfate could improve the product’s excipient profile, but any change would require comparative dissolution, bioequivalence and stability work. A surfactant substitution is commercially attractive only if it improves tolerability or manufacturing robustness without reducing exposure.

Could XENLETA support a pediatric formulation?

The strongest long-term excipient opportunity is an age-appropriate oral product. A 600 mg film-coated tablet is not suitable for young children. Potential dosage forms include:

• Powder for oral suspension.
• Reconstitutable granules.
• Taste-masked mini-tablets.
• Multiparticulates in capsules or sachets.
• Oral dispersible tablets for older children.

Lefamulin’s taste, dose flexibility and stability in aqueous suspension would determine the preferred platform. Taste masking is likely to require a polymer barrier or multiparticulate approach because simply adding sweetener may not overcome the active ingredient’s bitterness. A pediatric formulation would also need a robust preservative strategy if supplied as a multidose suspension.

Pediatric development is a regulatory and commercial issue, not only an excipient issue. XENLETA is approved for adults with CABP, and any pediatric indication would require supporting pharmacokinetic, safety and efficacy data under an FDA development plan.[1]

What excipients are important in XENLETA injection?

The intravenous formulation is supplied in a single-dose vial as a concentrated solution for dilution and infusion. Its excipient system must control pH, maintain solubility and provide acceptable osmolality after dilution.

The core injectable requirements are:

1. Chemical stability of lefamulin acetate during storage.
2. Protection from precipitation after dilution.
3. Compatibility with approved infusion fluids and administration sets.
4. Control of particulate matter and extractables.
5. Sterility and container-closure integrity.
6. Acceptable infusion tolerability.

The current vial format requires preparation before administration. A ready-to-use or premixed presentation could reduce pharmacy labor, preparation errors and administration delays. It would have particular value in emergency departments, smaller hospitals and outpatient parenteral antimicrobial therapy programs.

What injectable lifecycle products could compete with the current vial?

Product concept	Excipient or packaging requirement	Commercial opportunity
Ready-to-use infusion bag	Diluted stable solution with suitable container system	Reduces pharmacy compounding
Dual-chamber vial or bag	Separates drug and diluent until use	Extends stability while simplifying preparation
Smaller-volume concentrated vial	Optimized solubility and buffer system	Reduces shipping and storage burden
Premixed flexible bag	Low-adsorption, low-extractable polymer container	Supports hospital standardization
Extended-stability product	Improved buffer, antioxidant or oxygen-control strategy	Reduces wastage and increases inventory flexibility

A ready-to-use product may create the clearest hospital value, but it would require extensive compatibility studies. Lefamulin’s concentration, pH and stability after dilution would determine whether a premix can achieve a commercially useful shelf life.

When does XENLETA lose exclusivity?

XENLETA’s commercial exclusivity depends on several separate rights:

• FDA regulatory exclusivity.
• Orange Book-listed patents.
• Patent term adjustment or extension.
• Method-of-use claims covering CABP treatment.
• Formulation or salt claims.
• Manufacturing and process know-how.
• Any settlements with abbreviated new drug applicants.

The product was approved by the FDA in August 2019 for adult patients with CABP.[2] The approval did not create biologic-style reference-product exclusivity because XENLETA is a small-molecule antibiotic. The principal generic-entry barrier is therefore patent protection and the timing of ANDA approvals.

An accurate generic-entry forecast must distinguish between the expiration of an active-ingredient patent and later expiration dates for formulation, dosing or method-of-use patents. An ANDA applicant may challenge listed patents through a Paragraph IV certification, seek a non-infringing label or wait for patent expiry.

What is the Orange Book status of XENLETA?

The FDA Orange Book is the controlling source for listed patents, exclusivity codes and approved therapeutic-equivalence information. XENLETA should be assessed using the current Orange Book entry rather than relying on older investor materials, which may omit delisted patents, pediatric exclusivity changes or updated patent-term calculations.[3]

The relevant commercial questions are:

• Which patents are currently listed against the tablet and injection?
• Are claims directed to lefamulin itself, the acetate salt, formulations, dosing or methods of treatment?
• Has any ANDA applicant filed a Paragraph IV certification?
• Has XENLETA’s sponsor filed patent-listing corrections or litigation notices?
• Are any listed patents subject to a 30-month stay under the Hatch-Waxman framework?

Which companies are challenging XENLETA patents?

No reliable public conclusion should be drawn from the absence of a widely reported challenge. ANDA filings and Paragraph IV litigation can develop before they become visible in commercial summaries. The appropriate sources are FDA Orange Book updates, FDA Paragraph IV notifications when available, PACER litigation records and district-court complaints.

A generic challenge would most likely target one of four areas:

1. The active ingredient or salt.
2. The oral tablet composition.
3. The approved dosing regimen.
4. The CABP method of use.

The commercial effect of a challenge would depend on whether the generic applicant receives a full label, a carve-out label or approval after patent expiry. A skinny-label strategy could permit entry for non-protected uses while leaving branded sales in protected indications.

How strong is the XENLETA patent estate?

The estate is strategically stronger when it combines composition, formulation and method-of-use claims. It is weaker if protection depends mainly on a narrow clinical dosing claim that can be avoided through a label carve-out.

Patent-strength factors

Factor	Impact on strength
Broad composition claims	High value if valid and enforceable
Salt or polymorph claims	Moderate to high, depending on claim scope
Tablet formulation claims	Useful against direct copies, but vulnerable to design-around
Injection stability claims	Can delay ready-to-use competitors
CABP method claims	Potentially valuable, but vulnerable to skinny labels
Manufacturing-process claims	Stronger when difficult to reverse-engineer
Multiple independent patent families	Improves litigation leverage

Excipient-specific patents could strengthen lifecycle protection if they claim a narrow but commercially important formulation, such as a stable premix, pediatric suspension or improved dissolution system. They would not necessarily prevent a generic from using a different excipient architecture.

What commercial opportunities exist for XENLETA?

XENLETA has a differentiated clinical and formulation position because it offers both intravenous and oral administration for CABP. Its commercial opportunities are concentrated in settings where a single antibiotic can support hospital initiation and oral continuation.

Priority opportunities

Hospital-to-home therapy. An IV-to-oral pathway can reduce inpatient treatment duration when clinically appropriate. Packaging that simplifies the IV stage and a tablet that supports discharge planning can increase product value.

Outpatient infusion. A ready-to-use infusion bag or longer-stability presentation could improve use outside the acute-care hospital.

Formulary differentiation. Lefamulin’s pleuromutilin mechanism provides an alternative for patients with limited options because of allergy, intolerance or resistance concerns. The economic case depends on local resistance patterns and stewardship policies.

Pediatric expansion. A palatable, flexible oral formulation would create the largest formulation-led market extension, subject to regulatory development.

Geographic expansion. XENLETA’s commercial opportunity outside the United States depends on country-specific approval, reimbursement and antimicrobial stewardship requirements. Excipient sourcing must comply with regional pharmacopoeial standards, impurity controls and packaging regulations.

Hospital supply resilience. Dual sourcing for lactose, crospovidone, povidone, surfactants, buffers and container components can reduce manufacturing interruption risk. Injectable excipients and primary packaging require especially tight supplier qualification.

How does XENLETA compare with competing CABP antibiotics?

XENLETA competes with established agents such as moxifloxacin, levofloxacin, ceftaroline and omadacycline. Its commercial differentiation is based on mechanism, oral and IV availability, and the ability to treat adults with CABP under a defined short-course regimen.

Attribute	XENLETA	Fluoroquinolones	Omadacycline
Active ingredient	Lefamulin	Various	Omadacycline
Oral option	Yes	Yes	Yes
IV option	Yes	Yes	Yes
Excipient opportunity	Pediatric and premix lifecycle products	Mature generic markets	Oral and IV formulation competition
Main commercial constraint	Price, adoption and patent timing	Generic competition and safety restrictions	Administration and tolerability considerations

XENLETA’s formulation strategy must therefore protect convenience and minimize administration friction. A new excipient system has commercial value only if it improves one of those parameters or creates a defensible regulatory asset.

Key Takeaways

• XENLETA uses a high-dose oral tablet and a single-dose intravenous vial for adult CABP.
• The tablet’s key excipient functions are high-dose processing, wetting, disintegration and film coating.
• The most credible oral opportunities are lactose-free, smaller, better-tolerated and pediatric formulations.
• The most valuable injectable opportunity is a ready-to-use or premixed infusion product.
• Patent strength depends on the current Orange Book listing, claim scope, patent-term calculations and Paragraph IV activity.
• Pediatric development and hospital-use packaging offer more commercial potential than minor excipient substitution.
• Any formulation change must preserve lefamulin exposure despite the product’s food-administration restrictions.
• Supplier qualification, buffer stability, container compatibility and extractables control are central manufacturing barriers.

FAQs

Can XENLETA be reformulated as an oral suspension?

Yes, but the formulation would require taste masking, dose uniformity, chemical stability and multidose microbiological controls. A suspension could support pediatric development or patients unable to swallow tablets.

Is XENLETA a biologic with biosimilar risk?

No. Lefamulin is a small-molecule antibacterial drug. Competitive entry would proceed through the generic drug pathway, primarily under an ANDA, rather than through the biosimilar pathway.

Could a generic use different excipients from XENLETA?

Yes. Generic applicants generally do not need to duplicate every inactive ingredient. They must demonstrate pharmaceutical equivalence, bioequivalence and compliance with applicable safety and quality requirements.

Would a ready-to-use XENLETA infusion receive new patent protection?

Potentially. A premixed product could support patents directed to concentration, buffer system, container, stability, dilution or administration. Patentability would depend on novelty, non-obviousness and claim drafting.

What is the biggest commercial risk for XENLETA?

The largest risk is erosion of differentiation before a lifecycle product creates additional value. Generic entry, payer pressure, hospital stewardship controls and competition from established antibiotics can reduce the return on excipient and formulation investment.

References

1. U.S. Food and Drug Administration. (2023). XENLETA (lefamulin acetate) prescribing information. Nabriva Therapeutics plc.

2. U.S. Food and Drug Administration. (2019, August 19). FDA approves new antibiotic for treatment of community-acquired bacterial pneumonia. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm